Maine AIDS Care (Summer 1994)

Maine Medical Center’s AIDS Consultation Service

Follow this and additional works at: https://digitalcommons.usm.maine.edu/meaids_care

Recommended Citation
https://digitalcommons.usm.maine.edu/meaids_care/1

This Book is brought to you for free and open access by the Periodicals at USM Digital Commons. It has been accepted for inclusion in Maine AIDS Care by an authorized administrator of USM Digital Commons. For more information, please contact jessica.c.hovey@maine.edu.
From the earliest descriptions of AIDS in the United States, weight loss has been an initial complaint of a significant number of HIV-infected persons. In 1987, the CDC included HIV wasting syndrome as an indicator disease of AIDS in the revised surveillance case definition. Prospective and retrospective investigations have shown that 91% to 100% of people with AIDS lose weight. In a report published in 1990, the Federation of American Societies for Experimental Biology (FASEB) concluded that wasting and malnutrition were common occurrences in HIV disease; however, the extent of specific nutrient deficiencies was unclear and continues to be researched. Decrease in body weight, percent body fat, and body mass index have been observed in patients in the early stages of infection.

The development of malnutrition in patients with HIV infection is multifactorial and is thought to be an interplay between a decrease or alteration of food intake, malabsorption of ingested nutrients, and altered body metabolism characteristic of the disease process.

Factors contributing to reduced food intake include anorexia, oral or esophageal lesions, nausea and vomiting, diarrhea, and neurologic or psychologic complications. Additional factors related to reduced food intake may also include the presence and severity of fatigue and its impact on the patient's ability to obtain and prepare food; lack of money to buy food; lack of knowledge or interest in nutrition and HIV disease; and side effects of medications.

Nutritional malabsorption is related to small intestine injury, but disease of other digestive organs (ie. stomach, liver, pancreas) contribute as well. Researchers have identified three categories of intestinal disease: primary HIV infection of the enteroctyes, secondary involvement from systemic or otherwise disseminated disorders (ie. MAI, etc.), and a syndrome of inflammatory bowel disease that may be related to an identifiable pathogen or cancer. Patients with malabsorption do not increase intake sufficiently to compensate for lost calories. Systemic infections can also contribute to anorexia due to cytokine-mediated inhibition of appetite.

Persons with clinically stable HIV disease conserve lean body mass even with losses of body weight caused by decreased intake or malabsorption. However, patients with AIDS who have active disease, such as an opportunistic infection with fever, commonly are hypermetabolic and burn excessive calories, resulting in wasting. One research study reported metabolic rates 20-60% above predicted levels in HIV infected persons with acute systemic illness or with chronic infection. Another study reported that even in the absence of acute illness, persons infected with HIV had high rates of resting energy expenditure (REE) resulting in weight loss.

Kotler and colleagues studied the impact of malnutrition on survival of persons with AIDS and found that death from wasting in AIDS is related to the magnitude of tissue depletion and is independent of the underlying cause of wasting.

Stavudine (Zerit), a new reverse transcriptase inhibitor, has been approved by the FDA for treatment of HIV+ patients who can not tolerate or are not benefiting from other approved therapies (ie. AZT, DDI, DDC). It is not approved for use in combination antiretroviral therapy. The efficacy of Stavudine relative to other available antiretrovirals is still not clearly established. It is generally well tolerated, although 15-20% of patients may develop peripheral neuropathy which is usually reversible with discontinuation of the drug. The approved dose is 40 mg bid at a cost of approximately $186.00 for 60 capsules. Bristol Meyers Squibb Co. the manufacturer, will provide the drug to patients who can not afford it through an assistance program. For more information call Bristol-Meyers Squibb at 1-800-788-0213.
For patients with severe malnutrition, recent research has shown that enteral nutrition is preferable to parenteral nutrition in that enteral nutrition appears to preserve the gut function and maintain gut integrity. However, studies addressing the efficacy of enteral support in HIV+ patients remain scant. Low-fat, elemental formulas seem to work better with diarrhea and malabsorption syndromes.

Parenteral nutrition may be indicated for patients who demonstrate intolerance to enteral feedings, have bowel obstruction, severe pancreatitis, copious/high volume diarrhea, intractable vomiting, or in malnourished patients who require prolonged bowel rest. It should not be used in HIV+ patients who have functional GI tracts. Total parenteral nutrition (TPN) should not be used unless the prognosis warrants aggressive nutritional intervention. Some patients with end stage AIDS might be better supported with IV dextrose and vitamins and minerals to meet hydration and basic physiological needs without aggressive nutritional support. A key issue in the provision of TPN to patients with AIDS is the concern about infection. TPN can lead to systemic infections, and there may be a heightened risk in the AIDS patient.

The efficacy of TPN in the restoration of lean body mass HIV+ patients is under investigation. Studies show variable results on body composition, with increased fat stores seen in the majority of patients, but increased protein mass in only a few. They concluded that attempts to maintain body mass could prolong survival in persons with AIDS.

In AIDS patients, the disease related abnormalities in immune function make it difficult to interpret the effects of malnutrition on immune function in isolation from disease-related effects. However, deficiencies in essential nutrients may indeed compound the immunodeficiency characteristic of AIDS, rendering patients more susceptible to infections or exacerbating the severity of existing infections. Since not all patients with AIDS suffer from repeated infections, it is thought that the impaired immune system in AIDS patients may be better equipped to withstand certain environmental pathogens in the absence of malnutrition.

Numerous micronutrient deficiencies have been observed in HIV-infected patients. In one study of the prevalence of abnormalities of plasma vitamin and trace element concentrations in 30 HIV infected patients, one or more abnormalities were found in the majority of patients. There have been reports of low serum zinc, selenium, and vitamin B12 levels. The prevalence of folate deficiency is variable and depends on the dietary habits of individual patients. Deficiencies of vitamins A, E, B6, C, choline, and carotenes have also been noted.

These numerous micronutrient deficiencies may have detrimental effects on various organ systems, including the immune system, even in otherwise healthy individuals. It can thus be speculated that the deleterious effects of the immune system may be even greater in HIV infected persons, who already have a defective immune system from viral activity alone.

Some effects of malnutrition on immune functions are direct, while others are secondary, resulting from effects on other organ systems having immune regulatory functions or from the negative effects on all cellular metabolism, including cells of the immune system. Virtually all components of the immune system may be affected by malnutrition, including cell-mediated and humoral immunity, the complement system, the production of cytokines, and phagocytosis.

Because of the multifactorial nature of malnutrition in HIV disease, and because of the wide-ranging effects of malnutrition on the immune system, early monitoring, detection, and intervention regarding the nutritional management of HIV infected persons is essential. Each nutritional care plan should be individualized to meet the specific needs of the patient. It is imperative that the patient have an active role in the plan in an effort to optimize commitment and compliance.

Efforts to improve oral food intake are an important first step. These include providing nutritional counseling and education as soon as HIV disease is diagnosed, emphasizing adequate protein and calorie intake (high protein / high carbohydrate) and encouraging the appropriate servings of the four food groups. Supplementing the diet with multivitamin and mineral preparations containing 100% of the recommended daily allowance for all micronutrients is also appropriate. Although there is no scientific evidence that megadoses of any vitamin or mineral will alter the course of AIDS, much attention is being paid currently to so-called anti-oxidant therapies. We encourage careful scrutiny of these therapies, as further clinical trials are needed to confirm their efficacy and identify adverse side effects.

In addition to assuring adequate food intake of HIV-positive patients, development of rational strategies should be a high priority in their over-all care. It is imperative to rule out any and all causes of wasting, and to treat those underlying causes with drug or other appropriate therapy, while at the same time giving consideration to the best and most important nutritional strategies for that individual patient at that point in time.

If you have questions or concerns regarding HIV and Nutrition, the AIDS Consultation Service's Nutritional Consultant, Pamela Perkins is available for questions by calling the AIDS Information Hotline at 1-800-871-2701.
Clinical Strategies in Provision of Nutritional Support for Persons with HIV

I. Assessment of Nutritional Status

A. Regular chart of weight.
B. Consider referral to registered dietitian for complete assessment.
C. Key lab values to follow: albumin, cholesterol, triglycerides, H&H

II. General Principles of Nutrition for HIV

A. Encourage high calorie, nutrient dense foods.
B. Increase number and size of meals.
C. Use calorie containing condiments and add calorie containing supplements as needed.
D. Encourage daily multivitamin with 100% daily recommended allowances.

III. Other Strategies to Increase Calorie Intake in Patients with Weight Loss

A. Rule out opportunistic infection if low CD4 count (MAI, enteric parasites/bacteria)
B. Rule out depression if low calorie intake. (Refer to article on Depression & HIV)
C. Consider enteral supplementation
   1. Intact formulas (Protein derived from sodium & calcium caseinate, soy protein isolate, such as Ensure, Jevity, or Osmolite HN)
   2. Specific formulas
      - Fat malabsorption: (Modified fat such as Lipisorb)
      - Elemental: (Free amino acids such as Vivonex, Tolerex)
D. Consider appetite stimulation
   1. Megasteral acetate Megace (800 mg/d)
      *Note high cost and relatively small associated increase in lean body mass.*
   2. Dronabinol Marinol (5 mg/day)
      *Note high cost and relatively small associated increase in lean body mass.*
Common Medications Used in the Treatment of HIV That May Affect Appetite and Nutrition

<table>
<thead>
<tr>
<th>Medication</th>
<th>GI Side Affects</th>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZT</td>
<td>nausea, diarrhea (Common with high dosages early in treatment)</td>
<td>Take with food. Symptoms often improve with time. Consider decreasing dosage if persistent symptoms.</td>
</tr>
<tr>
<td>DDI</td>
<td>occasional nausea, diarrhea, pancreatitis (rare)</td>
<td>For minor GI symptoms, can consider switching between tablet and powder formulations.</td>
</tr>
<tr>
<td>DDC</td>
<td>Nausea (occasional), Mouth ulcers (rare)</td>
<td>Take with food.</td>
</tr>
<tr>
<td>D4T</td>
<td>Nausea (uncommon)</td>
<td>Take with food.</td>
</tr>
<tr>
<td>Bactrim</td>
<td>Nausea, diarrhea, Stomatitis (rare), Glossitis (rare)</td>
<td>Consider change from qd to 3x/week dose for pneumocystis prophylaxis.</td>
</tr>
<tr>
<td>Dapsone</td>
<td>Nausea (rare)</td>
<td>Consider change. Options include: 50 mg/d, 100 mg/qod, 200 mg/q week.</td>
</tr>
<tr>
<td>Rifabutin</td>
<td>Nausea, anorexia (rare)</td>
<td>Take with food. Consider split dose (ie. 150mg bid) for mycobacterium avium prophylaxis.</td>
</tr>
</tbody>
</table>

The AIDS Consultation Service's AIDS Information Hotline Pharmacist is available Monday - Friday 9:00 am - 4:00 pm to answer any questions you may have regarding medications used to treat HIV/AIDS and their side effects.
1-800-871-2701
In the evaluation of the patient with poor nutrition, depression should be considered. Depressive symptoms are not uncommon among HIV/AIDS patients. Depression may be initially manifested by weight loss and fatigue, which are common complaints of HIV disease. The challenge is to tease out symptoms that are an appropriate reaction to the disease from those that are due to HIV itself, and to determine whether or not a major depressive disorder is present. Some of the symptoms to consider are decreased mood, general anhedonia, significant weight loss or gain, insomnia or hypersomnia, motor agitation or retardation, fatigue, feelings of worthlessness, lack of concentration, recurrent thoughts of death, and over reaction to health issues. While considering these, it is beneficial to keep in mind that this patient may have had a predisposition to depression before the HIV/AIDS diagnosis, and to obtain careful history of previous mood disturbances, etc.

The following charts from AIDS Clinical Care provide a suggested approach to the treatment of depression in patients with HIV.

I. Depression Treatment

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>failed other treatments</td>
<td></td>
</tr>
<tr>
<td>other convincing evidence</td>
<td></td>
</tr>
<tr>
<td>yes</td>
<td>no</td>
</tr>
<tr>
<td>pharmacologic treatment</td>
<td></td>
</tr>
<tr>
<td>nonpharmacologic treatment</td>
<td></td>
</tr>
</tbody>
</table>

with psychotherapy

(psychotherapy)

II. Pharmacotherapy for Depression

<table>
<thead>
<tr>
<th>primary symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>poor sleep</td>
</tr>
<tr>
<td>weight loss</td>
</tr>
<tr>
<td>anxiety</td>
</tr>
<tr>
<td>GI disturbance</td>
</tr>
<tr>
<td>nortriptyline</td>
</tr>
<tr>
<td>desipramine</td>
</tr>
<tr>
<td>hyperomnia</td>
</tr>
<tr>
<td>weight gain</td>
</tr>
<tr>
<td>suicide potential</td>
</tr>
<tr>
<td>chronicity</td>
</tr>
<tr>
<td>fluxetine</td>
</tr>
<tr>
<td>sertraline</td>
</tr>
<tr>
<td>paroxetine</td>
</tr>
<tr>
<td>venlafaxine</td>
</tr>
</tbody>
</table>

failure from side effects

(switch call of antidepressants)

failure after good trial

lithium augmentation (risk/benefit)

next drug

III. Failed Drug Trial for Depression

principles: choose by side effects, case profile, what has failed, long-term plan

next drugs

bupropion

trazodone

alternate tricyclic

serotonin specific reuptake inhibitor

monoamine oxidase inhibitor

mood stabilizer augmentation

neuroleptic augmentation

benzodiazepine augmentation

Ritalin augmentation

Cytomel augmentation

sleep deprivat. augmentation

phototherapy

electroconvulsive therapy

On-Going Clinical Trials at AIDS Consultation Service

Delavirdine In Combination with AZT or DDI

Maine Medical Center's AIDS Consultation Service is enrolling in these two clinical trials of a new anti-retroviral drug, delavirdine, which is used in combination with AZT or DDI. Patient enrollment is expected to continue for 6 months. All antiviral medications, study related laboratory costs, and research clinical visits are provided at no cost to the patient. Physicians interested in referring patients for inclusion in this 2 year study should call the AIDS Consultation Service at 1-800-871-2701.

Open Label, Triple Antiviral Combination Drug Study (AZT, DDI or DDC, plus delavirdine)

Patients with progression of disease in the 2 studies noted above may, after 6 months on double combination therapy, enroll in this open label triple combination therapy trial. Antiretroviral medications, laboratory, and research visits will be free to the patient as in the other 2 delavirdine studies. The open label trial will continue for 2 years.
World AIDS Cases 2,500,000*
US AIDS Cases 361,509
US AIDS Deaths 220,871
Total US cases and deaths reported through 12/31/93

Maine AIDS Cases 530
Maine AIDS Deaths 279
Total Maine cases and deaths reported through 06/30/94

*Estimated

Upcoming HIV/AIDS Education

September 6, 1994
8:00 - 9:00 am
Outpatient Management of Grand Rounds...Family Practice Grand Rounds at Maine Medical Center
Presented by - Robert P. Smith, M.D. (207)871-2099

September 23, 1994
9:00 - 10:00 am
Pain Management in the Cancer and AIDS Patients...NE Osteopathic Association (207)474-2357
Presented by - Owen Pickus, D.O.

September 23, 1994
2:30 - 3:30 pm
HIV/AIDS Update for Physicians......NE Osteopathic Association (207)474-2357
Presented by - David Loughran, D.O.

September 26 & 27, 1994
HIV 101 & Care of PWA’s at Home...Hospice of Maine
Presented by - Sandra T. Putnam, RN, MSN, FNP (207)871-2099

September 27, 1994
Update from the International Conference on AIDS: Yokohama, Japan...Sponsored by New Eng. AIDS Ed. and Training Center

October 6, 7, 8, 1994
HIV/AIDS in the Dental Setting...Sponsored by New Eng. AIDS Ed. & Training Ctr - Maine at the Comfort Inn, Augusta, Me.

October 16, 1994
Women’s Health Care Issues Across the Life Span...Sponsored by University of Southern Maine at the Ramada Inn, Portland, Maine

November 2, 1994
Community Advocacy & Family Connections Contemporary Practice with HIV/AIDS...Sponsored by USM and ACS at Holiday Inn by the Bay, Portland, Me.

November 28, 1994
Psychosocial Issues & HIV...University of New England, Biddeford, Maine
Presented by - Jane K. O’Rourke, LCSW (207)871-2099

If you are providing an HIV/AIDS related educational session, please let us know at (207)871-2099

Maine Medical Center
AIDS Consultation Service
22 Bramhall Street
Portland, Maine 04102